Figure 6.

In vivo activity of BLU7482 in MCA205 mouse model on tumor volume (A), efficacy exposure (B), and tumor volume in individual mice (C). (A) Tumor growth curves of 8-week-old, female C57/BL6 MCA205-bearing mice (n = 10 per group) after treatment with either anti–PD-L1 monoclonal antibody alone (10 mg/kg i.p. day of treatment start and then 5 mg/kg every three days until study end [red line]), or in combination with 200 mg/kg QD of BLU7482 (green line). Vehicle group (blue line) had no treatment. The blue arrows denote anti–PD-L1 dosing. The zero time-point indicates the initiation of treatment. (B) Concentration−time curve of BLU7482. (C) Tumor growth curves of individual mice: left panel: vehicle (no treatment); middle panel: treated with anti–PD-L1 monoclonal antibody alone; right panel: treated with anti–PD-L1 and 200 mg/kg QD of BLU7482. EC₅₀, half maximal effective concentration; EC₉₀, 90% maximal effective concentration; IC₅₀, half maximal inhibitory concentration; IL-2, interleukin-2; i.p., intraperitoneal; anti–PD-L1, anti-programmed death-ligand 1; Q3D, every three days; QD, daily, SEM, standard error of the mean.